Effect of ezetimibe on PCSK9 concentrations in patients with type 2 diabetes and dyslipidemia

Effect of ezetimibe on PCSK9 concentrations in patients with type 2 diabetes and dyslipidemia - Effect of ezetimibe on PCSK9 concentrations in patients with type 2 diabetes and dyslipidemia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000018599

Enrollment

Registered

2015-08-08

Start date

2015-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Interventions

ezetimibe, 10mg/day after breakfast,for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: type 2 diabetes mellitus and hypercholesterolemia

Exclusion criteria

Exclusion criteria: 1)TG>400mg/dl 2)use of insulin 3)pregnant 4)allergy agignst treatment drug 5)severe liver disease 6)severe kideny disease 7)history of myocardial infarction or unstable angina within 3 months 8)secondary hyperlimidemia, drug-induced hyperlimidemia, familial hypercholeaterolemia 9)use of ezetimib or fibrate 10)subject who is not suitable for this study

Design outcomes

Primary

Measure	Time frame
Change in PCSK9 concentration after ezetimibe treatment	—

Countries

Japan

Contacts

Public ContactToru Miyoshi

Okayama University Hospital Cardiovascular Medicine

miyoshit@cc.okayama-u.ac.jp086-235-7351

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026